Growth Retardation, Reduced Invasiveness, and Impaired Colistin-Mediated Cell Death Associated with Colistin Resistance Development in Acinetobacter baumannii

ABSTRACT Two colistin-susceptible/colistin-resistant (Cols/Colr) pairs of Acinetobacter baumannii strains assigned to international clone 2, which is prevalent worldwide, were sequentially recovered from two patients after prolonged colistin administration. Compared with the respective Cols isolates (Ab248 and Ab299, both having a colistin MIC of 0.5 μg/ml), both Colr isolates (Ab249 and Ab347, with colistin MICs of 128 and 32 μg/ml, respectively) significantly overexpressed pmrCAB genes, had single-amino-acid shifts in the PmrB protein, and exhibited significantly slower growth. The Colr isolate Ab347, tested by proteomic analysis in comparison with its Cols counterpart Ab299, underexpressed the proteins CsuA/B and C from the csu operon (which is necessary for biofilm formation). This isolate also underexpressed aconitase B and different enzymes involved in the oxidative stress response (KatE catalase, superoxide dismutase, and alkyl hydroperoxide reductase), suggesting a reduced response to reactive oxygen species (ROS) and, consequently, impaired colistin-mediated cell death through hydroxyl radical production. Cols isolates that were indistinguishable by macrorestriction analysis from Ab299 caused six sequential bloodstream infections, and isolates indistinguishable from Ab248 caused severe soft tissue infection, while Colr isolates indistinguishable from Ab347 and Ab249 were mainly colonizers. In particular, a Cols isolate identical to Ab299 was still invading the bloodstream 90 days after the colonization of this patient by Colr isolates. These observations indicate considerably lower invasiveness of A. baumannii clinical isolates following the development of colistin resistance.

[1]  R. López-Rojas,et al.  Colistin Resistance in a Clinical Acinetobacter baumannii Strain Appearing after Colistin Treatment: Effect on Virulence and Bacterial Fitness , 2013, Antimicrobial Agents and Chemotherapy.

[2]  B. Devreese,et al.  A review on recent developments in mass spectrometry instrumentation and quantitative tools advancing bacterial proteomics , 2013, Applied Microbiology and Biotechnology.

[3]  R. Humphries,et al.  Colistin MIC Variability by Method for Contemporary Clinical Isolates of Multidrug-Resistant Gram-Negative Bacilli , 2013, Journal of Clinical Microbiology.

[4]  N. Soares,et al.  Extracellular proteome of a highly invasive multidrug-resistant clinical strain of Acinetobacter baumannii. , 2012, Journal of proteome research.

[5]  M. Sanguinetti,et al.  CspR, a Cold Shock RNA-Binding Protein Involved in the Long-Term Survival and the Virulence of Enterococcus faecalis , 2012, Journal of bacteriology.

[6]  E. Burd,et al.  Rapid Killing of Acinetobacter baumannii by Polymyxins Is Mediated by a Hydroxyl Radical Death Pathway , 2012, Antimicrobial Agents and Chemotherapy.

[7]  Rui Wang,et al.  Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. , 2012, The Journal of antimicrobial chemotherapy.

[8]  J. Pachón,et al.  Attenuated virulence of a slow-growing pandrug-resistant Acinetobacter baumannii is associated with decreased expression of genes encoding the porins CarO and OprD-like. , 2011, International journal of antimicrobial agents.

[9]  J. Vila,et al.  Growth of Acinetobacter baumannii in Pellicle Enhanced the Expression of Potential Virulence Factors , 2011, PloS one.

[10]  D. Raoult,et al.  Acinetobacter baumannii resistant to colistin with impaired virulence: a case report from France. , 2011, The Journal of infectious diseases.

[11]  K. Ko,et al.  Correlation between overexpression and amino acid substitution of the PmrAB locus and colistin resistance in Acinetobacter baumannii. , 2011, International journal of antimicrobial agents.

[12]  N. Woodford,et al.  Phosphoethanolamine Modification of Lipid A in Colistin-Resistant Variants of Acinetobacter baumannii Mediated by the pmrAB Two-Component Regulatory System , 2011, Antimicrobial Agents and Chemotherapy.

[13]  R. López-Rojas,et al.  Impaired virulence and in vivo fitness of colistin-resistant Acinetobacter baumannii. , 2011, The Journal of infectious diseases.

[14]  Jian Li,et al.  Colistin Resistance in Acinetobacter baumannii Is Mediated by Complete Loss of Lipopolysaccharide Production , 2010, Antimicrobial Agents and Chemotherapy.

[15]  L. Dijkshoorn,et al.  The Population Structure of Acinetobacter baumannii: Expanding Multiresistant Clones from an Ancestral Susceptible Genetic Pool , 2010, PloS one.

[16]  P. Higgins,et al.  Global spread of carbapenem-resistant Acinetobacter baumannii. , 2010, The Journal of antimicrobial chemotherapy.

[17]  S. Pournaras,et al.  Heteroresistance to Meropenem in Carbapenem-Susceptible Acinetobacter baumannii , 2009, Journal of Clinical Microbiology.

[18]  M. Adams,et al.  Resistance to Colistin in Acinetobacter baumannii Associated with Mutations in the PmrAB Two-Component System , 2009, Antimicrobial Agents and Chemotherapy.

[19]  D. Andreu,et al.  The cost of resistance to colistin in Acinetobacter baumannii: a proteomic perspective , 2009, Proteomics.

[20]  J. Pachón,et al.  Nosocomial Outbreak of Infection With Pan–Drug-Resistant Acinetobacter baumannii in a Tertiary Care University Hospital , 2009, Infection Control & Hospital Epidemiology.

[21]  J. Collins,et al.  A Common Mechanism of Cellular Death Induced by Bactericidal Antibiotics , 2007, Cell.

[22]  R. Bonomo,et al.  Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  A. Maniatis,et al.  Outbreak of multiple clones of imipenem-resistant Acinetobacter baumannii isolates expressing OXA-58 carbapenemase in an intensive care unit. , 2006, The Journal of antimicrobial chemotherapy.

[24]  P. Fournier,et al.  The epidemiology and control of Acinetobacter baumannii in health care facilities. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  G. Rossolini,et al.  Novel Acquired Metallo-β-Lactamase Gene, blaSIM-1, in a Class 1 Integron from Acinetobacter baumannii Clinical Isolates from Korea , 2005, Antimicrobial Agents and Chemotherapy.

[26]  P. Higgins,et al.  Selection of topoisomerase mutations and overexpression of adeB mRNA transcripts during an outbreak of Acinetobacter baumannii. , 2004, Journal of Antimicrobial Chemotherapy.

[27]  Seungok Lee,et al.  Prevalence of metallo-β-lactamase among Pseudomonas aeruginosa and Acinetobacter baumannii in a Korean University hospital and comparison of screening methods for detecting metallo-β-lactamase , 2003 .

[28]  R. Hancock,et al.  Peptide antibiotics , 1997, The Lancet.

[29]  D H Persing,et al.  Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing , 1995, Journal of clinical microbiology.

[30]  S. Pournaras,et al.  Global evolution of multidrug-resistant Acinetobacter baumannii clonal lineages. , 2013, International journal of antimicrobial agents.

[31]  U. Pennsylvania Clinical and Laboratory Standards Institute. , 2013 .

[32]  M. Ferraro Performance standards for antimicrobial susceptibility testing , 2001 .

[33]  John A. Kellen,et al.  Mechanisms of Multidrug Resistance , 1995 .